Community-acquired pneumonia caused by methicillin-resistant Staphylococcus aureus in a Chinese adult: A case report

Medicine (Baltimore). 2020 Jun 26;99(26):e20914. doi: 10.1097/MD.0000000000020914.

Abstract

Rationale: Methicillin-resistant Staphylococcus aureus (MRSA) has been established as an important cause of severe community-acquired pneumonia (CAP) with very high mortality. Panton-Valentine leukocidin (PVL) producing MRSA has been reported to be associated with necrotizing pneumonia and worse outcome. The incidence of community-acquired MRSA (CA-MRSA) pneumonia is very low, as only a few CA-MRSA pneumonia cases were reported in the last few years. We present a case of severe CAP caused by PVL-positive MRSA with ensuing septic shock.

Patient concerns: A 68-year-old male with no concerning medical history had developed a fever that reached 39.0°C, a productive cough that was sustained for 5 days, and hypodynamia. He was treated with azithromycin and alexipyretic in a nearby clinic for 2 days in which the symptoms were alleviated. However, 1 day later, the symptoms worsened, and he was taken to a local Chinese medicine hospital for traditional medicine treatment. However, his clinical condition deteriorated rapidly, and he then developed dyspnea and hemoptysis.

Diagnosis: CA-MRSA pneumonia and septic shock. The sputum culture showed MRSA. Polymerase chain reaction of MRSA isolates was positive for PVL genes.

Interventions: Mechanical ventilation, fluid resuscitation, and antibiotic therapy were performed. Antibiotic therapy included mezlocillin sodium/sulbactam sodium, linezolid, and oseltamivir.

Outcomes: He died after 12 hours of treatment.

Lessons: This is a report of severe pneumonia due to PVL-positive CA-MRSA in a healthy adult. CA-MRSA should be considered a pathogen of severe CAP, especially when combined with septic shock in previously healthy individuals.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Anti-Bacterial Agents / therapeutic use
  • Cough / etiology
  • Healthcare-Associated Pneumonia / drug therapy
  • Healthcare-Associated Pneumonia / etiology*
  • Healthcare-Associated Pneumonia / microbiology
  • Humans
  • Hypokinesia / etiology
  • Linezolid / therapeutic use
  • Male
  • Methicillin-Resistant Staphylococcus aureus / drug effects
  • Methicillin-Resistant Staphylococcus aureus / pathogenicity*
  • Mezlocillin / therapeutic use
  • Oseltamivir / therapeutic use
  • Shock, Septic / etiology
  • Shock, Septic / mortality
  • Shock, Septic / physiopathology
  • Staphylococcal Infections / complications*

Substances

  • Anti-Bacterial Agents
  • Oseltamivir
  • Linezolid
  • Mezlocillin